{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:32:03Z","timestamp":1762918323412,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Systemic sclerosis (SSc) patients are at risk for a severe disease course during SARS-CoV-2 infection either due to comorbidities or immunosuppression. The availability of SARS-CoV-2 vaccines is crucial for the prevention of this hard-to-treat illness. The aim of this study is to assess the humoral response after mRNA vaccination against SARS-CoV-2 in SSc patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Seropositivity rate and serum IgG levels were evaluated 1\u00a0month (t1) and 3\u00a0months (t3) after the second dose of vaccine in a cohort of SSc patients and healthy controls (HC). Differences were made with Student\u2019s or Mann\u2013Whitney\u2019s <jats:italic>t<\/jats:italic>-test and with the chi-square or Fisher exact test. Logistic regression model including immunosuppressive treatments (corticosteroids, CCS; mycophenolate mofetil, MMF; methotrexate, MTX; rituximab, RTX) was built to assess the predictivity for seropositivity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The seropositivity rate was similar in 78 SSc patients compared to 35 HC at t1 but lower at t3. SSc patients had lower serum IgG levels than HC at t1 but not at t3. SSc patients treated with immunosuppressive therapy showed both a lower seropositive rate (t1, 90.3% vs 100%; t3, 87.1% vs 97.9%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and serum IgG levels than untreated patients both at t1 [851 BAU\/ml (IQR 294\u20131950) vs 1930 BAU\/ml (IQR 1420\u20133020); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001] and t3 [266 BAU\/ml (IQR 91.7\u2013597) vs 706 BAU\/ml (IQR 455\u20131330); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001]. In logistic regression analysis, only MTX was significant [OR 39.912 (95% CI 1.772\u2013898.728); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SSc patients treated with MTX had a lower serological response to mRNA vaccine, and even low doses of CCS can adversely affect antibody titer and vaccination response.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 SSc patients are able to produce vaccine-induced antibodies after mRNA vaccination.<\/jats:italic><jats:italic>\u2022 In SSc patients, clinical characteristics of disease did not influence seropositivity rate.<\/jats:italic><jats:italic>\u2022 In SSc patients, even low doses of CCS can adversely affect antibody titer and vaccination response.<\/jats:italic><jats:italic>\u2022 In SSc patients, MTX treatment is mainly associated with reduced seropositivity and lower serum IgG levels.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-022-06219-7","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:02:41Z","timestamp":1653519761000},"page":"2755-2763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis"],"prefix":"10.1007","volume":"41","author":[{"given":"Chiara","family":"Pellicano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Campagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Leodori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Miglionico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Colalillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivano","family":"Mezzaroma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio Maria","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ombretta","family":"Turriziani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-8093","authenticated-orcid":false,"given":"Edoardo","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"6219_CR1","unstructured":"WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https:\/\/www.who.int. Accessed 23 Jan 2022."},{"key":"6219_CR2","unstructured":"Clinical characteristics of COVID-19. https:\/\/www.ecdc.europa.eu. Accessed 23 Jan 2022."},{"key":"6219_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054\u20131062. https:\/\/doi.org\/10.1016\/s0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"6219_CR4","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1080\/13685538.2020.1774748","volume":"23","author":"M Parohan","year":"2020","unstructured":"Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M (2020) Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male 23:1416\u20131424. https:\/\/doi.org\/10.1080\/13685538.2020.1774748","journal-title":"Aging Male"},{"key":"6219_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garc\u00eda-Su\u00e1rez","year":"2020","unstructured":"Garc\u00eda-Su\u00e1rez J, de la Cruz J, Cedillo \u00c1, Llamas P, Duarte R, Jim\u00e9nez-Yuste V et al (2020) Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol 13:133. https:\/\/doi.org\/10.1186\/s13045-020-00970-7","journal-title":"J Hematol Oncol"},{"key":"6219_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21:335\u2013337. https:\/\/doi.org\/10.1016\/s1470-2045(20)30096-6","journal-title":"Lancet Oncol"},{"key":"6219_CR7","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1111\/ajt.16185","volume":"20","author":"P Cravedi","year":"2020","unstructured":"Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, P\u00e9rez-S\u00e1ez MJ et al (2020) COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant 20:3140\u20133148. https:\/\/doi.org\/10.1111\/ajt.16185","journal-title":"Am J Transplant"},{"key":"6219_CR8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","volume":"70","author":"WH Self","year":"2021","unstructured":"Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ et al (2021) Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep 70:1337\u201343. https:\/\/doi.org\/10.15585\/mmwr.mm7038e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6219_CR9","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1001\/jama.2021.4385","volume":"325","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL et al (2021) Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 325:1784\u20131786. https:\/\/doi.org\/10.1001\/jama.2021.4385","journal-title":"JAMA"},{"key":"6219_CR10","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1001\/jama.2021.7489","volume":"325","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL et al (2021) Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325:2204\u20132206. https:\/\/doi.org\/10.1001\/jama.2021.7489","journal-title":"JAMA"},{"key":"6219_CR11","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1111\/ajt.16766","volume":"21","author":"VG Hall","year":"2021","unstructured":"Hall VG, Ferreira VH, Ierullo M, Ku T, Marinelli T, Majchrzak-Kita B et al (2021) Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant 21:3980\u20133989. https:\/\/doi.org\/10.1111\/ajt.16766","journal-title":"Am J Transplant"},{"key":"6219_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.kint.2021.07.005","volume":"100","author":"M Espi","year":"2021","unstructured":"Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E et al (2021) The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int 100:928\u2013936. https:\/\/doi.org\/10.1016\/j.kint.2021.07.005","journal-title":"Kidney Int"},{"key":"6219_CR13","doi-asserted-by":"publisher","first-page":"e150175","DOI":"10.1172\/jci150175","volume":"131","author":"A Sattler","year":"2021","unstructured":"Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H et al (2021) Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest 131:e150175. https:\/\/doi.org\/10.1172\/jci150175","journal-title":"J Clin Invest"},{"key":"6219_CR14","doi-asserted-by":"publisher","unstructured":"Karaba AH, Zhu X, Liang T, Wang KH, Rittenhouse AG, Akinde O, et al (2021) A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. Am J Transplant Published online: 24 December 2021. https:\/\/doi.org\/10.1101\/2021.08.11.21261914","DOI":"10.1101\/2021.08.11.21261914"},{"key":"6219_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330\u20131338. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220647","journal-title":"Ann Rheum Dis"},{"key":"6219_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","volume":"80","author":"Y Braun-Moscovici","year":"2021","unstructured":"Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K et al (2021) Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis 80:1317\u20131321. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220503","journal-title":"Ann Rheum Dis"},{"key":"6219_CR17","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","volume":"27","author":"AC Medeiros-Ribeiro","year":"2021","unstructured":"Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG et al (2021) Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med 27:1744\u20131751. https:\/\/doi.org\/10.1038\/s41591-021-01469-5","journal-title":"Nat Med"},{"key":"6219_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","volume":"80","author":"D Simon","year":"2021","unstructured":"Simon D, Tascilar K, Fagni F, Kr\u00f6nke G, Kleyer A, Meder C et al (2021) SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 80:1312\u20131316. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220461","journal-title":"Ann Rheum Dis"},{"key":"6219_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","volume":"80","author":"UM Geisen","year":"2021","unstructured":"Geisen UM, Berner DK, Tran F, S\u00fcmb\u00fcl M, Vullriede L, Ciripoi M et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80:1306\u20131311. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220272","journal-title":"Ann Rheum Dis"},{"key":"6219_CR20","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00296-021-04917-0","volume":"41","author":"S Cherian","year":"2021","unstructured":"Cherian S, Paul A, Ahmed S, Alias B, Manoj M, Santhosh AK et al (2021) Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol Int 41:1441\u20131445. https:\/\/doi.org\/10.1007\/s00296-021-04917-0","journal-title":"Rheumatol Int"},{"key":"6219_CR21","doi-asserted-by":"publisher","unstructured":"Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, et al (2021) Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. Published online: 23 March 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220289","DOI":"10.1136\/annrheumdis-2021-220289"},{"key":"6219_CR22","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","volume":"125","author":"C Ferri","year":"2021","unstructured":"Ferri C, Ursini F, Gragnani L, Raimondo V, Giuggioli D, Foti R et al (2021) Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups. J Autoimmun 125:102744. https:\/\/doi.org\/10.1016\/j.jaut.2021.102744","journal-title":"J Autoimmun"},{"key":"6219_CR23","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","volume":"80","author":"RH Haberman","year":"2021","unstructured":"Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M et al (2021) Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 80:1339\u20131344. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220597","journal-title":"Ann Rheum Dis"},{"key":"6219_CR24","doi-asserted-by":"publisher","unstructured":"Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Carri\u00e7o da Silva H, Yuki EFVN, et al (2021) SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology (Oxford). Published online: 11 December 2021. https:\/\/doi.org\/10.1093\/rheumatology\/keab886","DOI":"10.1093\/rheumatology\/keab886"},{"key":"6219_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1744666x.2019.1614915","volume":"15","author":"M Cutolo","year":"2019","unstructured":"Cutolo M, Soldano S, Smith V (2019) Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol 15:753\u2013764. https:\/\/doi.org\/10.1080\/1744666x.2019.1614915","journal-title":"Expert Rev Clin Immunol"},{"key":"6219_CR26","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"key":"6219_CR27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s11739-020-02557-z","volume":"16","author":"A Gigante","year":"2021","unstructured":"Gigante A, Villa A, Pellicano C, Rosato E (2021) In systemic sclerosis patients the anxiety disorder and Raynaud\u2019s phenomenon are increased during lock down period for COVID-19 pandemic. Intern Emerg Med 16:1095\u20131096. https:\/\/doi.org\/10.1007\/s11739-020-02557-z","journal-title":"Intern Emerg Med"},{"key":"6219_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/annrheumdis-2020-217407","volume":"79","author":"M Matucci-Cerinic","year":"2020","unstructured":"Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS et al (2020) Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis 79:724\u2013726. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217407","journal-title":"Ann Rheum Dis"},{"key":"6219_CR29","doi-asserted-by":"publisher","unstructured":"Gordon JK, Showalter K, Wu Y, Kwakkenbos L, Carrier ME, Henry RS, et al (2022) Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study. Lancet Rheumatol. Published online: 18 January 2022. https:\/\/doi.org\/10.1016\/s2665-9913(21)00416-1","DOI":"10.1016\/s2665-9913(21)00416-1"},{"key":"6219_CR30","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"6219_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/art.41734","volume":"73","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR et al (2021) American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1. Arthritis Rheumatol 73:1093\u20131107. https:\/\/doi.org\/10.1002\/art.41734","journal-title":"Arthritis Rheumatol"},{"key":"6219_CR32","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"6219_CR33","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/rheumatology\/keq097","volume":"49","author":"L Amanzi","year":"2010","unstructured":"Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S et al (2010) Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) 49:1374\u20131382. https:\/\/doi.org\/10.1093\/rheumatology\/keq097","journal-title":"Rheumatology (Oxford)"},{"key":"6219_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P et al (2017) The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis 76:270\u2013276. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209768","journal-title":"Ann Rheum Dis"},{"key":"6219_CR35","first-page":"2159","volume":"26","author":"TA Medsger Jr","year":"1999","unstructured":"Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159\u20132167","journal-title":"J Rheumatol"},{"issue":"Suppl 4","key":"6219_CR36","doi-asserted-by":"publisher","first-page":"iv43","DOI":"10.1093\/rheumatology\/kel310","volume":"45","author":"M Cutolo","year":"2006","unstructured":"Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C (2006) Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford) 45(Suppl 4):iv43-6. https:\/\/doi.org\/10.1093\/rheumatology\/kel310","journal-title":"Rheumatology (Oxford)"},{"key":"6219_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317","journal-title":"Eur Heart J"},{"key":"6219_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.05.00034505","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R et al (2005) ATS\/ERS Task Force. General considerations for lung function testing. Eur Respir J 26:153\u2013161. https:\/\/doi.org\/10.1183\/09031936.05.00034505","journal-title":"Eur Respir J"},{"key":"6219_CR39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cca.2021.10.035","volume":"523","author":"G Brisotto","year":"2021","unstructured":"Brisotto G, Muraro E, Montico M, Corso C, Evangelista C, Casarotto M et al (2021) IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers. Clin Chim Acta 523:476\u2013482. https:\/\/doi.org\/10.1016\/j.cca.2021.10.035","journal-title":"Clin Chim Acta"},{"key":"6219_CR40","doi-asserted-by":"publisher","first-page":"139.e1","DOI":"10.1016\/j.cmi.2021.08.023","volume":"28","author":"A Erice","year":"2022","unstructured":"Erice A, Varillas-Delgado D, Caballero C (2022) Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. Clin Microbiol Infect 28:139.e1-139.e4. https:\/\/doi.org\/10.1016\/j.cmi.2021.08.023","journal-title":"Clin Microbiol Infect"},{"key":"6219_CR41","doi-asserted-by":"publisher","first-page":"eabj6513","DOI":"10.1126\/sciimmunol.abj6513","volume":"6","author":"PS Heeger","year":"2021","unstructured":"Heeger PS, Larsen CP, Segev DL (2021) Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients. Sci Immunol 6:eabj6513. https:\/\/doi.org\/10.1126\/sciimmunol.abj6513","journal-title":"Sci Immunol"},{"key":"6219_CR42","doi-asserted-by":"publisher","first-page":"103733","DOI":"10.1016\/j.ebiom.2021.103733","volume":"74","author":"N Silvestris","year":"2021","unstructured":"Silvestris N (2021) What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients? EBioMedicine 74:103733. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103733","journal-title":"EBioMedicine"},{"key":"6219_CR43","doi-asserted-by":"publisher","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","volume":"74","author":"P Bergman","year":"2021","unstructured":"Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P et al (2021) Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 74:103705. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103705","journal-title":"EBioMedicine"},{"key":"6219_CR44","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s00392-021-01880-5","volume":"110","author":"R Schramm","year":"2021","unstructured":"Schramm R, Costard-J\u00e4ckle A, Rivinius R, Fischer B, M\u00fcller B, Boeken U et al (2021) Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol 110:1142\u20131149. https:\/\/doi.org\/10.1007\/s00392-021-01880-5","journal-title":"Clin Res Cardiol"},{"key":"6219_CR45","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.healun.2021.05.004","volume":"40","author":"J Havlin","year":"2021","unstructured":"Havlin J, Svorcova M, Dvorackova E, Lastovicka J, Lischke R, Kalina T et al (2021) Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant 40:754\u2013758. https:\/\/doi.org\/10.1016\/j.healun.2021.05.004","journal-title":"J Heart Lung Transplant"},{"key":"6219_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","volume":"28","author":"S Galmiche","year":"2022","unstructured":"Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P et al (2022) Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect 28:163\u2013177. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.036","journal-title":"Clin Microbiol Infect"},{"key":"6219_CR47","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","volume":"27","author":"RT Shroff","year":"2021","unstructured":"Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV et al (2021) Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med 27:2002\u20132011. https:\/\/doi.org\/10.1038\/s41591-021-01542-z","journal-title":"Nat Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06219-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T07:09:06Z","timestamp":1663139346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06219-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6219"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06219-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Declaration of Helsinki; the ethics committee of Sapienza University of Rome, Italy, reviewed and approved the research protocol, and written informed consent for participation has been obtained from the subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}